HDx Therapy

Expanded Hemodialysis may make a World of Difference for patients, clinicians & healthcare systems

One Change can Transform HD Treatment

HDx therapy enabled by Theranova dialyzer* brings us one step closer to the natural kidney.1 It helps with efficient removal of large-middle molecules (LMMs)2 which have been linked to inflammation, cardiovascular disease, and other co-morbidities in dialysis patients.3,4 

Consensus of Experts

Expanded Hemodialysis describes a treatment using a filter with a high molecular weight retention onset and a molecular weight cut-off similar to or exceeding high-flux HD.5,6 

Due to changes in filter geometry with a smaller inner diameter to promote internal filtration and back filtration, the volume of convective transport exceeds that of high-flux HD. This is combined with diffusive transport, without the use of replacement fluids.5,6 

This allows augmented clearances of molecules in a very broad spectrum of molecular weight from small water-soluble molecules to middle molecules with a molecular weight/size cutoff just below albumin.5,6 

Watch patient testimonial

Watch Robert Wahby share his story about undergoing HDx therapy and understand the science behind it with the renowned Dr. McIntyre.

patient reported outcomes

Patient-Reported Outcomes

HDx therapy enabled by the Theranova dialyzer may improve patient-reported outcomes.7,8,9
Patient-reported symptom burden has a significant impact on patient QoL.10

Economic Outcomes

Economic Outcomes

HDx therapy enabled by the Theranova dialyzer can help free resources and relieve the strain on healthcare systems17-19

 

  • HDx therapy enabled by the Theranova dialyzer may reduce hospitalization rates3,19  
  • HDx therapy enabled by the Theranova dialyzer has been associated with decreases in medication usage19-21
  • HDx therapy enabled by the Theranova dialyzer may reduce pressures on healthcare systems and total cost of care3,19-23

 

Expertise in membrane

Expertise in membrane manufacturing: MCO membrane to perform HDx therapy

Baxter’s membrane formation technologies have enabled precise control of pore size distribution which results in a narrow pore size distribution with a significant number of pores that are large enough for middle molecules to penetrate, but small enough for albumin to not pass through.1,24

Going Beyond Urea and Beta-2 Microglobulin

The clinical symptoms and conditions associated with uremic toxins differ according to their molecular weight, with the large-middle molecules being linked to several clinical effects.2

Evidence on Clinical Effectiveness

Supporting Material

Deep dive into the world of Expanded Hemodialysis enabled by the Theranova* dialyzer through our curated selection of downloadable material.

compendium of studies

Compendium of Studies

Explore how the evidence on patient-reported, clinical and economic outcomes continues to grow within HDx therapy.

HDx_page_600x260.png

Brochure

Discover how HDx therapy enabled by the Theranova* dialyzer may make a world of difference for patients, clinicians, and healthcare systems.

600x260_02.png

Data sheet

Detailed profiles of Theranova* dialyzers.

Learn more about HDx therapy

Important Safety Information

 Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.

*Do not use Theranova dialyzers in hemodiafiltration (HDF) or hemofiltration (HF) mode.

For safe and proper use of this device, please refer to Instructions for Use.

ce0123 logo